Virtus LifeSci Biotech Clinical Trials ETF
16 hedge funds and large institutions have $12.4M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2019 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
9.37% less ownership
Funds ownership: 39.02% → 29.65% (-9.4%)
Holders
16
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$479K | |
| 2 | +$357K | |
| 3 | +$166K | |
| 4 |
AG
Advisor Group
Phoenix,
Arizona
|
+$71K |
| 5 |
US Bancorp
Minneapolis,
Minnesota
|
+$39K |
Top Sellers
| 1 | -$1.2M | |
| 2 | -$332K | |
| 3 | -$197K | |
| 4 |
AWCI
Alpine Woods Capital Investors
Purchase,
New York
|
-$190K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$6K |